(193 days)
This membrane is intended for use in oral surgical procedures as a resorbable material for augmentation around implants placed in immediate extraction sockets, augmentation around implants placed in delayed extraction sockets; localized ridge augmentation for later implantation: alveolar ridge reconstruction for prosthetic treatment; filling of bone defects after root resection, cystectomy, removal of retained teeth; guided bone regeneration in dehiscence defects and guided tissue regeneration procedures in periodontal defects.
The TutoDent® Dental Membrane and CopiOs™ Pericardium Membrane are manufactured from bovine pericardium processed with the Tutoplast® process. These membranes are available in sizes ranging from 15 x 20mm to 30 x 40mm.
The provided text is a 510(k) summary for a medical device (TutoDent® Dental Membrane and CopiOs™ Pericardium Membrane) and the FDA's clearance letter. This type of regulatory document does not typically include detailed studies with acceptance criteria, sample sizes for test sets, ground truth establishment, or multi-reader multi-case studies as would be found in a clinical trial report for software or AI devices.
The core of this document is a claim of substantial equivalence to predicate devices, rather than a performance study against specific acceptance criteria. Therefore, most of the requested information regarding study design and performance metrics is not available in this document.
Here's an attempt to answer the questions based only on the provided text, highlighting what is missing:
Acceptance Criteria and Device Performance Study (as described in the document):
The document does not explicitly define acceptance criteria as a table of thresholds for performance metrics. Instead, "acceptance" in this context refers to the FDA's determination of substantial equivalence to legally marketed predicate devices. The study proving this "acceptance" is the 510(k) premarket notification process itself, where the applicant demonstrates that the new device has the same intended use and similar technological characteristics to existing devices.
1. Table of Acceptance Criteria and Reported Device Performance
| Criterion | Acceptance Threshold (Implicit from Substantial Equivalence) | Reported Device Performance |
|---|---|---|
| Intended Use | Same as predicate devices (TutoPatch membrane, Collagen Dental Membrane, Bio-Gide Resorbable Membrane, BioMend Extend) | "This membrane is intended for use in oral surgical procedures as a resorbable material for augmentation around implants placed in immediate extraction sockets... [and other uses listed]." This matches the intended uses of the predicate devices. |
| Technological Characteristics (Design & Function) | Similar to predicate devices (Collagen Dental Membrane, Bio-Gide Resorbable Membrane, BioMend Extend) | "The TutoDent® Dental Membrane, CopiOs™ Pericardium Membrane, Collagen Dental Membrane, Bio-Gide Resorbable Membrane and BioMend Extend have substantially equivalent design and function." |
| Material Composition & Processing | Same as predicate device (TutoPatch membrane) | "The TutoDent® Dental Membrane, CopiOs™ Pericardium Membrane and TutoPatch® membrane are composed of the same materials processed in the same manner." (Bovine pericardium processed with Tutoplast® process) |
2. Sample size used for the test set and the data provenance
- Not Applicable / Not Provided. This document is a regulatory submission for substantial equivalence based on material and functional comparison, not a clinical performance study with a "test set" in the context of an AI device. There is no mention of a test set, its size, or its provenance.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- Not Applicable / Not Provided. Ground truth establishment by experts for a test set is not part of a 510(k) submission for this type of device. The "ground truth" for substantial equivalence is the existence and characteristics of the predicate devices already on the market.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not Applicable / Not Provided. There is no mention of a test set or an adjudication method. The FDA's review process is an adjudication of the submitted evidence by internal reviewers, but not in the context of a "test set" as typically understood for AI performance studies.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No, a MRMC comparative effectiveness study was not done. This device is a resorbable membrane for oral surgery, not an AI-assisted diagnostic or imaging device. Therefore, the concept of "human readers improve with AI" is not relevant to this document.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not Applicable. This is a physical medical device (membrane), not an algorithm or software. Therefore, "standalone algorithm performance" is not relevant.
7. The type of ground truth used
- The "ground truth" for this 510(k) submission is the documented characteristics and regulatory status of the legally marketed predicate devices. The applicant is demonstrating that their new device is fundamentally similar to these existing, cleared devices.
8. The sample size for the training set
- Not Applicable / Not Provided. This is not an AI device, so there is no training set in the computational sense. The "training" for the substantial equivalence claim comes from the existing knowledge and data regarding the predicate devices.
9. How the ground truth for the training set was established
- Not Applicable / Not Provided. As this is not an AI device, the concept of a training set and its ground truth establishment does not apply.
{0}------------------------------------------------
161
MAY 12 2008
RTI BIOLOGICS
ADVANCING SCIENCE, SAFETY & INNOVATION
510(K) Summary
April 17, 2008 Date:
Submitted by: Lisa Simpson RTI Biologics, Inc. 11621 Research Circle Alachua. FL 32615 Phone: 386-418-8888 x4326 Fax: 386-462-3821
| Proprietary Names: | TutoDent® Dental Membrane |
|---|---|
| CopiOs™ Pericardium Membrane | |
| Common Name: | Barrier, Animal Source, Intraoral |
Classification: Unclassified
Code Section: None
Substantial Equivalence:
The TutoDent® Dental Membrane and CopiOs™ Pericardium Membrane are substantially equivalent to the TutoPatch membrane with respect to materials. The TutoDent® Dental Membrane and CopiOs™ Pericardium Membrane are substantially equivalent to the Collagen Dental Membrane, Bio-Gide Resorbable Membrane and BioMend Extend predicate devices with respect to design and function.
Description:
The TutoDent® Dental Membrane and CopiOs™ Pericardium Membrane are manufactured from bovine pericardium processed with the Tutoplast® process. These membranes are available in sizes ranging from 15 x 20mm to 30 x 40mm.
Intended Use:
This membrane is intended for use in oral surgical procedures as a resorbable material for augmentation around implants placed in immediate extraction sockets, augmentation around implants placed in delayed extraction sockets; localized ridge augmentation for later implantation: alveolar ridge reconstruction for prosthetic treatment; filling of bone defects after root resection, cystectomy, removal of retained teeth; guided bone regeneration in dehiscence defects and guided tissue regeneration procedures in periodontal defects.
Summary of Technological Characteristics:
The TutoDent® Dental Membrane, CopiOs™ Pericardium Membrane, Collagen Dental Membrane, Bio-Gide Resorbable Membrane and BioMend Extend have substantially equivalent design and function. The TutoDent® Dental Membrane, CopiOs™ Pericardium Membrane and TutoPatch® membrane are composed of the same materials processed in the same manner.
11621 Research Greia + Algchua, FL 32016 + P.O Box 2650 + Alachoa, FL 32016 2660 Tel 386 418.8888 · 877.343.6892 · Fax 388.410.0342 · Customer Service 800.624.7238 · www.rtir.com
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the department's name around the perimeter. In the center is an abstract symbol that resembles an eagle or bird-like figure with stylized wings.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAY 12 2008
Ms. Lisa Simpson Director, Regulatory Affairs RTI Biologics, Incorporated P.O. Box 2650 11621 Research Circle Alachua, Florida 32616-2650
Re: K073097
Trade/Device Name: TutoDent® Dental Membrane CopiOs™ Pericardium Membrane Regulation Number: 21 CFR 872.3930 Regulation Name: Bone Graft Material Regulatory Class: II Product Code; NPL Dated: April 17, 2008 Received: April 18, 2008
Dear Ms. Simpson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{2}------------------------------------------------
Page 2 - Ms. Simpson
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
Suyte Y. Michaelonis
Chiu Lin. Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Indications for Use:
510(k) Number (if known):
Device Name:
TutoDent® Dental Membrane CopiOs™ Pericardium Membrane
Indications For Use:
This membrane is intended for use in oral surgical procedures as a resorbable material for augmentation around implants placed in immediate extraction sockets, augmentation around implants placed in delayed extraction sockets; localized ridge augmentation for later implantation; alveolar ridge reconstruction for prosthetic treatment; filling of bone defects after root resection, cystectomy, removal of retained teeth; guided bone regeneration in dehiscence defects and guided tissue regeneration procedures in periodontal defects.
V Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED)
'목록========================================================================================================================================================================== Concurrence of CDRH, Office of Device Evaluation (ODE)
K. Muly for MSM
(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices
510(k) Number: K073097
Page 1 of 1
4-2
§ 872.3930 Bone grafting material.
(a)
Identification. Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.(b)
Classification. (1) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)(2) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.